钠–葡萄糖协同转运蛋白2抑制剂在肺癌中的研究进展
Research Progress of Sodium-Glucose Co-Transporter Protein-2 Inhibitors in Lung Cancer
DOI: 10.12677/acm.2024.14102810, PDF,   
作者: 林晓倩, 江德鹏*：重庆医科大学附属第二医院呼吸与危重医学科，重庆
关键词: 糖尿病；肺癌；钠–葡萄糖协同转运蛋白2抑制剂；Diabetes； Lung Cancer； SGLT-2 Inhibitor
摘要: SGLT-2 (钠–葡萄糖协同转运蛋白2)抑制剂是一种新型降糖药，它作用于肾脏，能够降低肾脏重新吸收葡萄糖的能力，促使尿糖排泄量增加，最终达到降低血糖水平的效果。近年来，SGLT-2被发现不仅具有降糖的作用，还可以通过抑制葡萄糖代谢、抑制血管生成、影响免疫微环境等多个机制起到抗肿瘤的作用。目前，SGLT-2抑制剂在肺癌中的作用的研究仍处于初步阶段，这篇综述系统地阐述了SGLT-2抑制剂在肺癌中的研究进展，希望能为未来SGLT-2抑制剂在肺癌中的应用提供参考。
Abstract: SGLT-2 (sodium-glucose co-transporter protein-2) inhibitor is a new type of hypoglycemic drug, which acts on the kidneys and can reduce the kidney’s ability to reabsorb glucose, prompting an increase in urinary glucose excretion, and ultimately achieving the effect of lowering blood glucose levels. In recent years, SGLT-2 has been found to not only have a hypoglycemic effect, but also play an anti-tumor role by inhibiting glucose metabolism, inhibiting angiogenesis, affecting the immune microenvironment and other mechanisms. At present, the research on the role of SGLT-2 inhibitors in lung cancer is still in the preliminary stage, and this review systematically describes the research progress of SGLT-2 inhibitors in lung cancer, hoping to provide a reference for the future application of SGLT-2 inhibitors in lung cancer.
文章引用：林晓倩, 江德鹏. 钠–葡萄糖协同转运蛋白2抑制剂在肺癌中的研究进展[J]. 临床医学进展, 2024, 14(10): 1375-1381. https://doi.org/10.12677/acm.2024.14102810

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231.
[3] 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2023版) [J]. 中华肿瘤杂志, 2023, 45(7): 539-574.
[4] Qi, J., He, P., Yao, H., Song, R., Ma, C., Cao, M., et al. (2019) Cancer Risk among Patients with Type 2 Diabetes: A Real‐World Study in Shanghai, China. Journal of Diabetes, 11, 878-883. [Google Scholar] [CrossRef] [PubMed]
[5] Tsilidis, K.K., Kasimis, J.C., Lopez, D.S., Ntzani, E.E. and Ioannidis, J.P.A. (2015) Type 2 Diabetes and Cancer: Umbrella Review of Meta-Analyses of Observational Studies. BMJ, 350, g7607. [Google Scholar] [CrossRef] [PubMed]
[6] Kim, D. and Scherer, P.E. (2021) Obesity, Diabetes, and Increased Cancer Progression. Diabetes & Metabolism Journal, 45, 799-812. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, N., Tang, H., Liu, F. and Hong, Q. (2020) Prolonged Progression-Free Survival and Overall Survival Are Associated with Diabetes Mellitus but Inversely Associated with Levels of Blood Glucose in Patients with Lung Cancer. Chinese Medical Journal, 133, 786-791. [Google Scholar] [CrossRef] [PubMed]
[8] Brancher, S., Støer, N.C., Weiderpass, E., Damhuis, R.A.M., Johannesen, T.B., Botteri, E., et al. (2020) Metformin Use and Lung Cancer Survival: A Population-Based Study in Norway. British Journal of Cancer, 124, 1018-1025. [Google Scholar] [CrossRef] [PubMed]
[9] 任婧, 肖新华. 对钠-葡萄糖共转运蛋白2抑制剂获益机制的再认识[J]. 中华糖尿病杂志, 2023, 15(7): 656-661.
[10] O’Hara, D.V., Lam, C.S.P., McMurray, J.J.V., Yi, T.W., Hocking, S., Dawson, J., et al. (2024) Applications of SGLT2 Inhibitors beyond Glycaemic Control. Nature Reviews Nephrology, 20, 513-529. [Google Scholar] [CrossRef] [PubMed]
[11] Zheng, J., Lu, J., Qi, J., Yang, Q., Zhao, H., Liu, H., et al. (2024) The Effect of SGLT2 Inhibition on Prostate Cancer: Mendelian Randomization and Observational Analysis Using Electronic Healthcare and Cohort Data. Cell Reports Medicine, 5, Article ID: 101688. [Google Scholar] [CrossRef] [PubMed]
[12] Alblowy, A.H., Maan, N. and Ibrahim, A.A. (2023) Optimal Control Strategies for SGLT2 Inhibitors as a Novel Anti-Tumor Agent and Their Effect on Human Breast Cancer Cells with the Effect of Time Delay and Hyperglycemia. Computers in Biology and Medicine, 166, Article ID: 107552. [Google Scholar] [CrossRef] [PubMed]
[13] Xie, Z., Wang, F., Lin, L., Duan, S., Liu, X., Li, X., et al. (2020) An SGLT2 Inhibitor Modulates SHH Expression by Activating AMPK to Inhibit the Migration and Induce the Apoptosis of Cervical Carcinoma Cells. Cancer Letters, 495, 200-210. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, Y., Yang, L., Mao, L., Zhang, L., Zhu, Y., Xu, Y., et al. (2022) SGLT2 Inhibition Restrains Thyroid Cancer Growth via G1/S Phase Transition Arrest and Apoptosis Mediated by DNA Damage Response Signaling Pathways. Cancer Cell International, 22, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[15] Nakano, D., Kawaguchi, T., Iwamoto, H., Hayakawa, M., Koga, H. and Torimura, T. (2020) Effects of Canagliflozin on Growth and Metabolic Reprograming in Hepatocellular Carcinoma Cells: Multi-Omics Analysis of Metabolomics and Absolute Quantification Proteomics (IMPAQT). PLOS ONE, 15, e0232283. [Google Scholar] [CrossRef] [PubMed]
[16] Xu, D., Zhou, Y., Xie, X., He, L., Ding, J., Pang, S., et al. (2020) Inhibitory Effects of Canagliflozin on Pancreatic Cancer Are Mediated via the Downregulation of Glucose Transporter1 and Lactate Dehydrogenase A. International Journal of Oncology, 57, 1223-1233. [Google Scholar] [CrossRef] [PubMed]
[17] Hung, M., Chen, Y., Chen, L., Chu, P., Hsieh, F., Tsai, M., et al. (2019) Canagliflozin Inhibits Growth of Hepatocellular Carcinoma via Blocking Glucose-Influx-Induced β-Catenin Activation. Cell Death & Disease, 10, Article No. 420. [Google Scholar] [CrossRef] [PubMed]
[18] Cui, C., Zhou, X., Zhang, W., Qu, Y. and Ke, X. (2018) Is β-Catenin a Druggable Target for Cancer Therapy? Trends in Biochemical Sciences, 43, 623-634. [Google Scholar] [CrossRef] [PubMed]
[19] Kaji, K., Nishimura, N., Seki, K., Sato, S., Saikawa, S., Nakanishi, K., et al. (2017) Sodium Glucose Cotransporter 2 Inhibitor Canagliflozin Attenuates Liver Cancer Cell Growth and Angiogenic Activity by Inhibiting Glucose Uptake. International Journal of Cancer, 142, 1712-1722. [Google Scholar] [CrossRef] [PubMed]
[20] Dutka, M., Bobiński, R., Francuz, T., Garczorz, W., Zimmer, K., Ilczak, T., et al. (2022) SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives. Cancers, 14, Article 5811. [Google Scholar] [CrossRef] [PubMed]
[21] Wu, W., Zhang, Z., Jing, D., Huang, X., Ren, D., Shao, Z., et al. (2022) SGLT2 Inhibitor Activates the STING/IRF3/IFN-β Pathway and Induces Immune Infiltration in Osteosarcoma. Cell Death & Disease, 13, Article No. 523. [Google Scholar] [CrossRef] [PubMed]
[22] Anastasio, C., Donisi, I., Del Vecchio, V., Colloca, A., Mele, L., Sardu, C., et al. (2024) SGLT2 Inhibitor Promotes Mitochondrial Dysfunction and ER-Phagy in Colorectal Cancer Cells. Cellular & Molecular Biology Letters, 29, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[23] Ding, L., Chen, X., Zhang, W., Dai, X., Guo, H., Pan, X., et al. (2023) Canagliflozin Primes Antitumor Immunity by Triggering PD-L1 Degradation in Endocytic Recycling. Journal of Clinical Investigation, 133, e154754. [Google Scholar] [CrossRef] [PubMed]
[24] Okada, J., Yamada, E., Saito, T., Yokoo, H., Osaki, A., Shimoda, Y., et al. (2020) Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules, 25, Article 495. [Google Scholar] [CrossRef] [PubMed]
[25] Zhou, J., Zhu, J., Yu, S., Ma, H., Chen, J., Ding, X., et al. (2020) Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibition Reduces Glucose Uptake to Induce Breast Cancer Cell Growth Arrest through AMPK-mTOR Pathway. Biomedicine & Pharmacotherapy, 132, Article ID: 110821. [Google Scholar] [CrossRef] [PubMed]
[26] Lymperopoulos, A., Borges, J.I., Cora, N. and Sizova, A. (2021) Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland. International Journal of Molecular Sciences, 22, Article No. 7684. [Google Scholar] [CrossRef] [PubMed]
[27] Chang, A., Botteri, E., Gillis, R.D., Löfling, L., Le, C.P., Ziegler, A.I., et al. (2023) Beta-Blockade Enhances Anthracycline Control of Metastasis in Triple-Negative Breast Cancer. Science Translational Medicine, 15, eadf1147. [Google Scholar] [CrossRef] [PubMed]
[28] Villani, L.A., Smith, B.K., Marcinko, K., Ford, R.J., Broadfield, L.A., Green, A.E., et al. (2016) The Diabetes Medication Canagliflozin Reduces Cancer Cell Proliferation by Inhibiting Mitochondrial Complex-I Supported Respiration. Molecular Metabolism, 5, 1048-1056. [Google Scholar] [CrossRef] [PubMed]
[29] Biziotis, O., Tsakiridis, E.E., Ali, A., Ahmadi, E., Wu, J., Wang, S., et al. (2023) Canagliflozin Mediates Tumor Suppression Alone and in Combination with Radiotherapy in Non‐Small Cell Lung Cancer (NSCLC) through Inhibition of HIF‐1α. Molecular Oncology, 17, 2235-2256. [Google Scholar] [CrossRef] [PubMed]
[30] Scafoglio, C.R., Villegas, B., Abdelhady, G., Bailey, S.T., Liu, J., Shirali, A.S., et al. (2018) Sodium-Glucose Transporter 2 Is a Diagnostic and Therapeutic Target for Early-Stage Lung Adenocarcinoma. Science Translational Medicine, 10, eaat5933. [Google Scholar] [CrossRef] [PubMed]
[31] Yamamoto, L., Yamashita, S., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Shigeoka, T., et al. (2021) Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Attenuates Lung Cancer Cell Proliferation in Vitro. Diabetology International, 12, 389-398. [Google Scholar] [CrossRef] [PubMed]
[32] Saggese, P., Pandey, A., Alcaraz, M., Fung, E., Hall, A., Yanagawa, J., et al. (2023) Glucose Deprivation Promotes Pseudohypoxia and Dedifferentiation in Lung Adenocarcinoma. Cancer Research, 84, 305-327. [Google Scholar] [CrossRef] [PubMed]
[33] Hsieh, M., Choe, J.H., Gadhvi, J., Kim, Y.J., Arguez, M.A., Palmer, M., et al. (2019) P63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Reports, 28, 1860-1878.e9. [Google Scholar] [CrossRef] [PubMed]
[34] Luo, J., Hendryx, M. and Dong, Y. (2023) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Non-Small Cell Lung Cancer Survival. British Journal of Cancer, 128, 1541-1547. [Google Scholar] [CrossRef] [PubMed]
[35] Xiao, Y., Yang, W. and Wang, M. (2024) SGLT2 Inhibitors May Reduce Non-Small Cell Lung Cancer and Not Increase Various Neoplasms Including Several Skin Cancers. Endocrine. [Google Scholar] [CrossRef] [PubMed]
[36] Shapiro, S.B., Yin, H., Yu, O.H.Y. and Azoulay, L. (2024) Sodium‐Glucose Cotransporter‐2 Inhibitors and the Risk of Lung Cancer among Patients with Type 2 Diabetes. British Journal of Clinical Pharmacology, 90, 1365-1370. [Google Scholar] [CrossRef] [PubMed]

为你推荐